Goldline Pharmaceutical Limited has issued an intimation to BSE Limited regarding an upcoming meeting of its Board of Directors. The meeting is scheduled to be held on Saturday, November 14, 2026, at the company's Registered Office located at 103, F-1, Leela Apartment, Shilpa Hsg Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, India, 440015.
The primary business to be transacted at this meeting is:
- Consideration and approval of the Standalone Unaudited Financial Results for the half-year ended September 30, 2026. These results will be presented in compliance with applicable Accounting Standards and will be accompanied by a Statement of Assets and Liabilities.
The company states that the outcome of this board meeting will be filed with the exchange separately following the meeting.
The communication is digitally signed by Ruchi Sanket Modi, who holds the position of Company Secretary cum Compliance Officer for Goldline Pharmaceutical Limited.